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Background: The objective of this study was to describe the clinical and microbiological characteristics of
bloodstream infections (BSIs) due to AmpC producing Enterobacteriaceae (AE) in a large centralized Canadian region
over a 9-year period.
Methods: An active surveillance cohort design in Calgary, Canada.
Results: A cohort of 458 episodes of BSIs caused by AE was assembled for analysis. The majority of infections were of
nosocomial origin with unknown sources. Enterobacter spp. was the most common species while BSIs due to Serratia
spp. had a significant higher mortality when compared to other AE. Delays in empiric or definitive antibiotic therapy
were not associated with a difference in outcome. However, patients that did not receive any empiric antimicrobial
therapy had increased mortality (3/5; 60% vs. 57/453; 13%; p = 0.018) as did those that did not receive definitive
therapy (6/17; 35% vs. 54/441; 12%; p = 0.015).
Conclusions: Delays in therapy were not associated with adverse outcomes although lack of active therapy was
associated with increased mortality. A strategy for BSIs due to AE where β-lactam antibiotics (including oxyimino-
cephalosporins) are used initially followed by a switch to non-β-lactam antibiotics once susceptibility results are
available is effective.
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cefotaxime, ceftazidime), 7-α-methoxy-cephalosporins (i.e.
cephamycins such as cefoxitin) and monobactams by* Correspondence: vikas.chaubey@albertahealthservices.ca
1Department of Community Health Sciences, University of Calgary, TRW
Building 3rd Floor, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada
2Department of Medicine, Administration Office, Foothills Medical Centre -
North Tower, University of Calgary, 9th Floor, 1403 - 29th Street NW, Calgary,
AB T2N 2T9, Canada
Full list of author information is available at the end of the article
© 2014 Chaubey et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.overproducing their chromosomal AmpC β-lactamases
[1]. In Klebsiella pneumoniae, Salmonella spp., and Pro-
teus mirabilis, that lack chromosomal β-lactamases, this
type of resistance can be mediated by plasmid encoded
or imported AmpC cephalosporinases [2]. Escherichia
coli possesses genes encoding for chromosomal non-
inducible AmpC β-lactamases that are regulated by
weak promoters and strong attenuators resulting in low
amounts of the cephalosporinase [3]. Occasionally,
cephamycin-resistant E. coli can also carry plasmid-
mediated AmpC β-lactamases [2].
There is controversy about the optimal antibiotic ther-
apy for severe infections caused by AmpC producingal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that are chromosomally mediated because of the potential
for inducibility and selection of derepressed mutants [4-7].
Clinical and Laboratory Standards Institute (CLSI) recom-
mends reporting β-lactam susceptibilities of these or-
ganisms, with a footnote suggesting that resistance may
develop during therapy [8]. Literature has shown the
importance of early appropriate antibiotic therapy for
severe infections in preventing mortality, [9] but few stud-
ies have looked at serious infections caused by AE espe-
cially those with chromosomal enzymes. Cephalosporin
resistant Enterobacteriaceae have been isolated from pa-
tients that have previously received broad-spectrum ceph-
alosporins, [10-12] and emergence of cephalosporin
resistance has been described during therapy with β-
lactams [13,14]. These studies have focused on a single
species of AE, [10-12,14] or have included a limited
range of organisms [13]. In addition, these studies have
included various types of infections and have not clearly
demonstrated that therapy with β-lactams is associated
with an increase in mortality.
The objective of this study is to describe the clinical and
microbiological characteristics of bloodstream infections
(BSIs) due to AE in a large centralized Canadian region
over a 9-year period (2000–08). We also investigate the ef-
fects of various empiric and definitive antimicrobial treat-
ment regimens on the mortality of patients with BSIs due
to AE. Specifically, we look to determine if definitive treat-
ment with β-lactam antibiotics are associated with in-
creased mortality in infections caused by AE.
Methods
Study population
The Calgary Zone of Alberta Health Services (previously
known as the Calgary Health Region) administers virtually
all medical and surgical care to the residents of the cities
of Calgary and Airdrie and a large surrounding area
(population 1.2 million) in the province of Alberta,
Canada. All patients with BSIs caused by AE from January
1, 2000 to December 31st, 2008 in the Calgary Zone were
included in the study. The Conjoint Health Research Eth-
ics Board at the University of Calgary approved this study
and granted a waiver of individual patient consent.
We excluded episodes with incomplete data, polymicro-
bial episodes and those in which the patients died within
24 hours (which may have precluded their receiving ap-
propriate therapy). To investigate the effects of various
empiric and definitive antimicrobial treatment regimens
on the mortality of patients, patients were divided into
two groups. Group I included patients that received
definitive therapy with β-lactams that are hydrolyzed
by AmpC β-lactamases (i.e. piperacillin-tazobactam),
oxyimino-cephalosporins (i.e. cefotaxime, ceftriaxone,
ceftazidime) and monobactams (i.e. aztreonam). GroupII included patients that received definitive therapy
with non-β-lactams and/or β-lactams with sufficient ac-
tivity in spite of AmpC β-lactamases (i.e. cefepime and
carbapenems).
Study protocol
An active surveillance cohort design was utilized. Surveil-
lance for AE were identified using the Electronic Sur-
veillance System at Calgary Laboratory Services [15].
International Statistical Classification of Disease and
Health Related Problems (ICD) codes were translated
into Charlson Comorbidity Scores using standardized
algorithms [16,17]. Antimicrobial therapies were deter-
mined using a regional pharmacy database. AE BSIs
were defined by the isolation of such bacteria from at
least one set of aseptically obtained blood cultures. Re-
peat isolation from blood from the same patient within
365 days was considered to be the same incident
infection.
Definitions
Empiric therapy was defined as that therapy initiated prior
to the availability of blood culture results and sensitivities.
Time to first therapy was defined as the time from blood
culture draw to receipt of the first dose of antibiotics. Ad-
equate therapy was defined by the receipt of a standard
parenteral dose of an antimicrobial to which the organism
was susceptible in vitro or a standard oral dose of an anti-
microbial with sufficient bioavailability, to which the or-
ganism was susceptible in vitro. If the patient received two
drugs from different classes to which the bacterium tested
susceptible to one agent but resistant to the other agent,
the therapy was considered to be adequate. Adequacy of
combination antibiotic therapy required the microorgan-
ism to be susceptible to all drugs in the combination. De-
finitive therapy was defined as the final antibiotic chosen
to complete a treatment course after the availability of
antimicrobial susceptibilities. If the patient was given ad-
equate antibiotics before or at the time of acquiring the
blood culture, the time to first adequate therapy was re-
corded as zero hours. Mortality was defined as the 30-day
mortality of patients as determined by searching provin-
cial databases. Definitions of nosocomial, healthcare asso-
ciated and community-acquired infections used in this
study, have previously been described [18].
Laboratory methods
Clinical isolates were identified and minimum inhibitory
concentrations (MICs) were determined by Vitek 2™
(Vitek AMS; bioMérieux Vitek Systems Inc., Hazelwood,
MO). Susceptibility testing and reporting was performed
according to the CLSI guidelines for broth dilution [8].
Enterobacteriaceae potentially possessing chromosom-
ally mediated AmpC β-lactamases did not undergo
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ibility of these genes.
These included: Citrobacter spp. (C. braakii, C. freundii,
C. youngae), Enterobacter spp. (E. aerogenes, E. asburiae,
E. cancerogenus, E. cloacae, E. sakazakii), Hafnia alvei,
Morganella morganii, Providencia spp. (P. rettgeri, P.
stuartii) and Serratia spp. (S. liquefaciens, S. marcescens,
S. odorfera) [5].
After isolates were first shown to be non-susceptible to
cefoxitin, the presence of AmpC β-lactamases in E. coli, K.
pneumoniae and Salmonella isolates was confirmed using
previously described boronic acid methodology [19].
The policy of the centralized microbiology laboratory is
to suppress the susceptibility results of all β-lactam antibi-
otics for potential AE. Only fluoroquinolones, aminoglyco-
sides and trimethoprim/sulfamethoxazole are routinely
reported for infections caused by potential AE. Cefepime
and carbapenem susceptibilities are available upon request.
Statistical analysis
Analysis was performed using Stata version 10.0 (Stata
Corp, College Station, TX). Non-normally distributed
data were described using medians with interquartile
ranges (IQR). Categorical data were compared using the
two-sided Fisher’s exact test. P-values less than 0.05 were
considered significant. Logistic regression models were
developed to assess the independent effects of various
factors on mortality. Treatment adequacy and timing, and
all factors found to be significant to the P < 0.1 level in
univariate analyses were included in the initial models.
Backward stepwise variable elimination was then per-
formed to develop the most parsimonious model. Dis-
crimination was assessed using the area under the receiver
operator characteristic (ROC) curve and calibration using
the Hosmer-Lemeshow goodness-of-fit test.
Results
Study population
Five hundred and ninety incident episodes of AE BSIs
were identified between 2000 and 2008. After excluding
patients with incomplete data (n = 64), polymicrobial in-
fection (n = 54, 9) or that died within 24 hours of culture
draw (n = 14) a cohort of 458 (78%) episodes remained
for further analysis.
Clinical characteristics (see Table 1 for further details)
The median patient age was 62.5 years (IQR, 43.6-
75.6 years), 283 (62%) were male, and the median age-
adjusted Charlson score was 4 (IQR, 4–11). The majority
of infections were nosocomially-acquired (n = 232, 51%)
and patients most often presented with primary BSIs (n =
224, 50%). The most common comorbid condition was
malignancy (n = 81, 18%). BSIs due to AE remained stableover the time period; however we did notice a slight in-
crease in 2008.
Microbiological characteristics (see Table 1 for further
details)
Enterobacter (n = 225, 49%), Serratia (n = 73, 16%) and
Citrobacter (n = 51, 11%) species were the most common
bacteria responsible for BSIs due to AE. Ciprofloxacin,
gentamicin, tobramycin, cefepime and imipenem showed
excellent activity against various AE (excluding E. coli)
with susceptibility ranging from 89%-100%. E. coli with
AmpC β-lactamases showed the highest levels of resist-
ance to ciprofloxacin (20%), gentamicin (23%), and tobra-
mycin (13%). Excluding primary BSIs, there was a strong
association of Enterobacter spp. with the presence of
underlying BTIs (46/255, 18%) while the isolation of Citro-
bacter and Providencia/Morganella spp were associated
with underlying UTIs.
Outcomes (see Table 2 for further details)
Overall 60 (13%) patients died within thirty days. S.
marcescens had the highest mortality (15/52; 29%) and
Citrobacter spp. had the lowest mortality (1/51; 2.0%).
Description of therapy (see Tables 2 and 3 for further
details)
Empiric therapy was provided in 453 (99%) cases.
The most common agents used as empiric therapy in-
cluded piperacillin-tazobactam (131, 29%) and oxyimino-
cephalosporins (106, 23%). Empiric therapy was started
immediately in 172 (38%) patients, within 8 hours in 277
(60%) patients, within 24 hours in 391 (85%) patients and
within 48 hours in 427 (93%) patients. The timing of em-
piric antibiotic therapy was not associated with a differ-
ence in outcome. However, patients that did not receive
empiric antimicrobial therapy had a worse outcome (3/5;
60% vs. 57/453; 13%; p = 0.018). The number, combination
(at least two antibiotics from different classes), or class of
antibiotic was also not associated with any statistically
significant improvement in outcome (data not shown).
Empiric therapy with piperacillin-tazobactam or an
oxyimino-cephalosporin was not associated with a differ-
ence in mortality outcome (28/237; 12% vs. 32/221; 14%;
p = 0.41). Of 131 that received empiric piperacillin-
tazobactam, the case-fatality rate was 2/19 (11%) for
those patients with isolates that tested resistant at base-
line as compared to 13/112 (12%) for those isolates that
tested sensitive, p = 0.89. Notably, of 106 patients who
received oxyimino-cephalosporins as empiric therapy,
the case-fatality rate was 5/18 (28%) for those patients
with isolates that tested resistant at baseline as compared
to 8/88 (9%) for those that were sensitive, p = 0.04.
Adequate therapy was provided in 441 (96%) cases. The
most common agents used as adequate therapy included
Table 1 Clinical and microbiological characteristics of bloodstream infections due to AmpC-producing Enterobacteriaceae
in the Calgary Zone
Enterobacter spp.1 Serratia spp.2 Citrobacter spp.3 Providencia &
Morganella spp.4
E. coli5 Other6
No. of episodes 255 73 51 39 30 10
Source of infection (no. episodes)
Biliary 46 2 6 2 3 4
Bowel 18 5 4 4 2 0
Urinary 43 10 13 15 5 2
Pneumonia 14 13 2 0 1 0
CVS source 0 1 0 0 0 0
SST source 7 4 0 0 0 0
BJ source 1 0 2 4 0 0
CNS source 1 0 0 0 0 0
Unknown 125 38 24 14 19 4
Comorbid conditions
Myocardial infarction 15 (5.9%) 4 (5.5%) 4 (7.8%) 4 (10%) 2 (6.7%) 0 (0%)
CHF 32 (13%) 18 (25%) 5 (9.8%) 6 (15%) 2 (6.7%) 1 (10%)
PVD 6 (2.4%) 7 (9.6%) 1 (2.0%) 4 (10%) 2 (6.7%) 1 (10%)
CVD 8 (3.1%) 5 (6.8%) 1 (2.0%) 2 (5.1%) 0 (0%) 1 (10%)
Dementia 2 (<1%) 0 (0%) 2 (3.9%) 3 (8.5%) 1 (3.3%) 0 (0%)
CPD 20 (7.8%) 13 (18%) 2 (3.9%) 5 (13%) 8 (27%) 3 (30%)
Rheumatic disease 2 (<1%) 0 (0%) 1 (2.0%) 3 (8.5%) 0 (0%) 0 (0%)
Peptic ulcer disease 9 (3.5%) 4 (5.5%) 1 (2.0%) 2 (5.1%) 0 (0%) 1 (10%)
Hemiplegia/Paraplegia 6 (2.4%) 4 (5.5%) 2 (3.9%) 3 (8.5%) 1 (3.3%) 0 (0%)
Renal disease 31 (12%) 17 (23%) 7 (14%) 9 (23%) 2 (6.7%) 0 (0%)
Mild liver disease 10 (3.9%) 1 (1.4%) 1 (2.0%) 0 (0%) 0 (0%) 0 (0%)
Moderate severe liver disease 12 (4.7%) 4 (5.5%) 1 (2.0%) 2 (5.1%) 2 (6.7%) 1 (10%)
Malignancy 53 (21%) 8 (11%) 15 (29%) 2 (5.1%) 1 (3.3%) 2 (20%)
Metastatic solid cancer 27 (11%) 3 (4.1%) 2 (3.9%) 1 (2.6%) 5 (17%) 1 (10%)
DM w/o complication 25(9.8%) 7 (9.6%) 2 (3.9%) 4 (10%) 3 (10%) 0 (0%)
DM w/ complications 14 (5.5%) 6 (8.2%) 3 (5.9%) 6 (15%) 1 (3.3%) 0 (0%)
Median Charlson (IQR) 3 (1–5) 4 (2–6) 3 (2–4) 4 (3–7) 4 (1–5) 4 (4–6)
Median age (IQR) 58.0 (39 – 72.3) 65.6 (52.1 – 74.2) 59.1 (36.6 – 75.3) 72.9 (62.9 – 79.6) 58.6 (41.1 – 77.3) 71.2 (64.4 – 81.6)
Male sex (%) 62% 60% 75% 74% 33% 50%
Surveillance definition
Nosocomial 138 (24, 17% ) 45 (14, 31%) 22 (1, 4.5%) 13 (2, 15%) 11 (0, 0%) 3 (0, 0%)
HCAI 70 (6, 8.6%) 12 (1, 8.3%) 16 (0, 0%) 17 (3, 18%) 10 (1, 10%) 4 (0, 0%)
Community acquired 47 (3, 6.4%) 16 (3, 19%) 13 (0, 0%) 9 (1, 11%) 9 (0, 0%) 3 (1, 33%)
p-value 0.08 0.248 1.000 1.000 0.633 0.600
Per year of infection
2000 20 (7.8%) 6 (8.2%) 2 (3.9%) 7 (18%) 0 (0%) 1 (10%)
2001 26 (10%) 13 (18%) 3 (5.9%) 0 (0%) 4 (13%) 3 (30%)
2002 24 (9.4%) 5 (6.9%) 5 (9.8%) 1 (2.6%) 4 (13%) 1 (10%)
2003 33 (13%) 3 (4.1%) 3 (5.9%) 9 (23%) 5 (17%) 2 (20%)
2004 31 (12%) 9 (12%) 8 (16%) 3 (7.7%) 2 (6.7%) 2 (20%
2005 20 (7.8%) 14 (19%) 8 (16%) 8 (21%) 2 (6.7%) 1 (10%)
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Table 1 Clinical and microbiological characteristics of bloodstream infections due to AmpC-producing Enterobacteriaceae
in the Calgary Zone (Continued)
2006 24 (9.4%) 6 (8.2%) 5 (9.8%) 5 (13%) 7 (23%) 0 (0%)
2007 31 (12%) 7 (9.6%) 10 (20%) 2 (5.1%) 2 (6.7%) 0 (0%)
2008 46 (18%) 10 (14%) 7 (14%) 4 (10%) 4 (13%) 0 (0%)
Susceptibility testing
(percentage susceptible)
Ciprofloxacin 248/255 (98%) 71/73 (97%) 47/50 (94%) 36/38 (95%) 24/30 (80%) 10/10 (100%)
Gentamicin 251/255 (99%) 72/73 (99%) 45/50 (90%) 34/38 (90%) 23/30 (77%) 10/10 (100%)
Piperacillin-tazobactam 203/255 (80%) 69/73 (95%) 46/50 (92%) 38/38 (100%) 29/30 (97%) 7/10 (70%)
TMP/SMX 242/255 (95%) 73/73 (100%) 39/50 (78%) 31/38 (82%) 19/30 (63%) 10/10 (100%)
Tobramycin 251/255 (99%) 64/73 (88%) 45/50 (90%) 33/38 (87%) 26/30 (87%) 10/10 (100%)
Imipenem 255/255 (100%) 73/73 (100%) 50/50 (100%) 38/38 (100%) 30/30 (100%) 10/10 (100%)
1Includes 34 E. aerogenes, 1 E. asburiae, 2 E. cancerogenus, 210 E. cloacae, 6 E. sakazakii and 2 E. spp bacteremia episodes.
2Includes 3 S. liquefaciens, 67 S. marcescens, 1 S. odorfera and 2 S. spp. bacteremia episodes.
3Includes 17 C. braakii, 30 C. freundii, 2 C. spp. and 2 C. youngae bacteremia episodes.
4Includes 27M. Morganii, 3 P. rettgeri and 9 P. stuartii bacteremia episodes.
5Includes 30 E. coli bacteremia episodes.
6Includes 7 H. alveii, 2 Salmonella spp. and 1 K. pneumoniae bacteremia episodes.
CVS = Cardiovascular, SST = Skin and Soft Tissue, BJ = Bone and Joint, CNS = Central Nervous System, CHF = Congestive Heart Failure, PVD = Peripheral Vascular
Disease, CVD = Cerebrovascular Disease, CPD = Chronic Pulmonary Disease, TMP/SMX = Trimethoprim/Sulfamethoxazole.
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cephalosporins (106, 23%). Adequate therapy was re-
ceived immediately in 98 (21%) patients, within 8 hours
in 194 (42%) patients, within 24 hours in 327 (71%)
patients and within 48 hours in 389 (85%) patients. Early
receipt of adequate antibiotic therapy was not associated
with improved outcomes. Adequate number, combination
(at least two antibiotics from different classes to which the
microorganism had in vitro susceptibility) or class of anti-
biotic was not associated with improved outcome (data
not shown). First adequate therapy with piperacillin-
tazobactam or an oxyimino-cephalosporin was not associ-
ated with different outcomes (28/241; 12% vs. 32/217;
15%; p = 0.33). Patients that did not receive any form of
definitive therapy did have a worse outcome (6/17; 35% vs.
54/441; 12%; p = 0.015). The analysis that assessed the
outcomes of patients in groups I and II did not reveal a
mortality difference (Group I: 4/22; 18% vs. Group II: 50/
419; 12%, p = 0.33) or a differences in relapse of infection
with the same bacteria (Group I: 3/22; 14% vs. Group II:
27/419, 6.4%, p = 0.182).
Logistic regression model (see Table 4 for further details)
A logistic regression model was developed to assess
the effect of timing and adequacy of therapy (n = 458)
and had good calibration (Hosmer-Lemeshow goodness
of fit p = 0.49 and discrimination (area under ROC =
0.808; ROC curve not shown). Early adequate therapy
between 8–24 hours after blood culture draw had worse
outcomes (Odds Ratio (OR) 2.01, p = 0.050) while de-
layed therapy at T > 24 hours to T = 48 hours had in-
creased survival that did not reach statistical significance(OR 0.44, p = 0.70). Never having received definitive
therapy demonstrated an increased risk of death (OR
4.78, p = 0.013).
Discussion
Our study described the clinical and microbiological char-
acteristics of BSIs due to AE over a 9-year period. The
majority of infections were of nosocomial origin with un-
known sources. Patients often had underlying malignancy
and the highest rates of mortality were associated with
underlying pneumonia. Enterobacter spp. was by far the
most common bacteria responsible for BSIs due to AE
and was associated with underlying BTIs. Interestingly, we
found that BSIs due to Serratia spp. had a significant
higher mortality when compared to other AE.
As demonstrated in our study, previous studies of AE
BSIs have consistently shown Enterobacter spp. as the
most common microbiologic etiology, [20-23] and ma-
lignancy as the most common underlying condition
[10,21-29]. The most common sources of AE BSIs from
the literature include unknown source, biliary source
and urinary source (variably ranked), in studies includ-
ing either a single species or multiple species of AE
[10,23-27]. Our study is unique in that the mortality of
Serratia spp. BSIs is particularly high relative to what
others have found [21].
Early and adequate antimicrobial therapy is a corner-
stone of treatment of severe infections including BSIs.
Several studies have found a clear relationship between
time to first adequate therapy and mortality [9,30-32].
Most of these studies utilize in vitro susceptibility to estab-
lish adequacy of therapy and this may not be appropriate
Table 2 Factors investigated for association with 30-day case fatality (univariate analysis)
Factor Case fatality with factor Case fatality without factor Relative-risk (95% ci) P-value
Male 42/283 (15%) 18/175(10%) 1.44 (0.86-2.42) 0.20
*Age-adjusted Charlson >median (4) 48/230 (21%) 12/228 (5.3%) 3.97 (2.16-7.26) <0.001






Skin and soft tissue infection 3/11 (28%)
Bone and joint 2/7 (29%)
CNS 0/1 (0%)
CVS 0/1 (0%)
Location of acquisition 0.015
Nosocomial 41/232 (17.7%)
Healthcare associated 11/129 (8.5%)
Community-acquired 8/97 (8.2%)
Microbiology** 0.012
Enterobacter spp. 33/255 (13%)
E. aerogenes 5/34 (15%)
E. asburiae 0/1 (0%)
E. cancerogenus 0/2 (0%)
E. cloacae 26/210 (13%)
E. sakazakii 2/6 (33%)
E. spp. 0/2 (0%)
Serratia spp. 18/73 (25%)
S. liquefaciens 2/3 (66%)
S. marcescens 15/67 (22%)
S. odorfera 1/1 (100%)
S. spp. 0/2 (0%)
Citrobacter spp.** 1/51 (2.0%)
C. braakii 0/17 (0%)
C. freundii 1/30 (3.3%)
C. spp. 0/2 (0%)
C. youngae 0/2 (0%)
Escherichia coli 1/30 (3.3%)
Morganella morganii 4/27 (15%)
Providencia spp. 2/12 (17%)
P. rettgeri 1/3 (33%)
P. stuartii 1/9 (11%)
Hafnei alvei 1/7 (14%)
Salmonella spp. 0/2 (0%)
Klebsiella pneumoniae 0/1 (0%)
Plasmid mediated 1/33 (3.0%) 59/425 (14%) 0.22(0.03-1.53) 0.10
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Table 2 Factors investigated for association with 30-day case fatality (univariate analysis) (Continued)
Description of empiric therapy 0.12
Empiric therapy in hours at:
t = 0 23/172 (13%)
t > 0 and t = 8 11/105 (10%)
t >8 and t = 24 17/114 (15%)
t > 24 and t = 48 3/36 (8.3%)
Empiric at t > 48 hrs. 3/26 (12%)
Never received empiric therapy. 3/5 (60%)
Description of adequate therapy 0.05
Adequate therapy in hours at:
t = 0 hrs. 11/98 (11%)
t > 0 and t = 8 11/96 (11%)
t >8 and t = 24 23/133 (17%)
t > 24 and t = 48 5/62 (8.1%)
t > 48 hrs. 4/52 (7.7%)
Never received adequate or definitive therapy. 6/17 (35%)
CNS: Central Nervous System. CVS: Cardiovascular System. 95% CI: 95% Confidence Interval.
*Charlson data was missing for 11 patients; their Charlson score was assumed to be zero and then adjusted for age.
**Some isolates were not speciated beyond the genus level.
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that delays in active antibiotic therapy were not associated
with a poor outcome. However, patients that did not re-
ceive any empiric or definitive antimicrobial therapy had
increased mortality. While the importance of appropriate
early antimicrobial therapy is generally accepted, there are
several studies that do not support this premise [33-37].
Our patient population was not limited to the critically ill
and this may explain why we were not able to demon-
strate an association between early adequate antimicrobial
therapy and increased survival.
Previous studies have investigated the issue of resist-
ance development during treatment with oxyimino-
cephalosporins of infections due to AE. A previous study
had shown a low risk of emergence of resistance during
therapy and a low risk of associated mortality [13]. How-
ever that study included only a select number of AE and
included a broad range of infections types. Another
study showed that after treatment, 477 patients with sus-
ceptible Enterobacter spp. infections, 49 (10.3%) subse-
quently developed cephalosporin resistant isolates [11].
This study did not specifically address mortality. The
policy of the centralized laboratory to suppress suscepti-
bilities for all β-lactam antibiotics for infections caused
by AE resulted in clinicians changing the definitive
antimicrobial therapy to non-β-lactam antibiotics once
susceptibility results were available. After excluding all
patients that died early and that did not receive defini-
tive therapy only 22 of 441 patients completed defini-
tive therapy with oxyimino-cephalosporins. The low
numbers of patients treated with oxyimino-cephalosporinsthus precluded us from determining the efficacy of this
regimen. Our study did however reveal that patients em-
pirically treated with oxyimino-cephalosporins, when the
isolate was resistant at baseline, had a statistically worse
outcome. This supports the notion that initial empiric
therapy with oxyimino-cephalosporins may be effect-
ive for AE that test in vitro sensitive to these agents.
We recommend that patients who previously received
oxyimino-cephalosporins should be treated empirically
with an alternate class of agent because of the risk of
being colonized with oxyimino-cephalosporin resistant
AE.
In the multivariate model it was noted that adequate
therapy at between 8–24 hours after blood culture draw
had worse outcomes while delayed adequate therapy at
T > 24 hours to T = 48 hours had increased survival;
findings that did not reach statistical significance. Our
group has previously reported similar results [34]. This
interesting finding was most likely the result of sicker
patients receiving broader and more prompt empiric an-
timicrobials as a result of their clinical condition. Again,
our study is limited in that we did not collect data re-
garding severity of illness. Furthermore, since these find-
ings did not reach statistical significance they may have
occurred by chance alone. It should be mentioned that
the numbers of patients that did not receive empiric or
definitive therapy were small, 5 and 17 respectfully. As
such, any specific conclusions could not be generated.
There are several limitations of our study mostly aris-
ing from our pharmacy database. This database did not
capture all outpatient data. It is conceivable that the 22
Table 3 *Empiric, first adequate and definitive antimicrobial choice and associated 30-day case-fatality










Antibiotics with activity against AmpC-
producing Enterobacteriaceae












Carbapenem 0/16 (0%) Carbapenem 3/31 (9.7%) Carbapenem 5/45 (11%)
Cefepime 1/3 (33%) Cefepime 1/5 (20%) Cefepime 1/4 (25%)
Cefoxitin 0/1 (0%) Cefixime 0/10 (0%) Cefotaxime 0/2 (0%)
Ceftazidime 1/15 (6.7%) Ceftazidime 0/10 (0%) Ceftazidime 0/1 (0%)
Ceftriaxone 11/85 (13%) Ceftriaxone 12/97 (12%) Ceftriaxone 1/7 (14%)
Cefuroxime 1/5 (20%) Colistin 0/1 (0%) Colistin 0/1 (0%)




Fluoroquinolone 10/76 (13%) TMP/SMX 0/9 (0%) TMP/SMX 0/14 (0%)
TMP/SMX 2/14 (14%)














*For each category the total number of episodes adds up to more than the actual number of episodes because some patients received multiple antibiotics
corresponding to each time period.
Table 4 Logistic regression model
Variable Odds ratio 95% CI P-value
Age adjusted Charlson score (per point) 1.34 1.20-1.49 <0.001
Source of infection
Biliary (reference)
Bowel 3.87 1.27-11.80 0.018
Pneumonia 12.98 4.49-37.46 <0.001
SSTI 12.64 2.35-68.07 0.003
Unknown 2.24 1.04-4.822 0.039
Treatment group
Adequate therapy at T = 8-24 hours. 2.01 1.00-4.03 0.050
Adequate therapy at T > 24 hours to T = 48 hours. 0.44 0.18-1.07 0.70
Never received definitive therapy. 4.78 1.39-16.44 0.013
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having completed definitive β-lactam therapy may have
received outpatient definitive non-β-lactam therapy after
initial improvement. In addition, the pharmacy database
may have not captured all ward stock antibiotics dis-
pensed and the pharmacy database captured the time
the antibiotic was dispensed which may not have corre-
lated with the time the antibiotic was administered. Fi-
nally, the cohort assembled for this study included
potential AmpC producers, and it is possible that some
of the isolates may not have had the AmpC β-lactamase
gene. In the clinical context it is impractical due to time
and financial constraints to test each isolate for the pres-
ence of the AmpC gene and/or inducibility of these
genes. As such our study attempted to answer this ques-
tion from a feasibility perspective.
Conclusion
In conclusion, Enterobacter spp. is the most common AE
that causes BSIs in the Calgary region. A strategy where
β-lactam therapy (including oxyimino-cephalosporins) is
used as initial therapy for severe infections caused by AE
followed by a switch to non-β-lactam therapy once sus-
ceptibility results are available is effective. The efficacy of
using oxyimino-cephalosporins as definitive therapy for
severe AE infections remains unknown.
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